162 related articles for article (PubMed ID: 30027525)
21. Silencing of the
Bugara B; Durbas M; Kudrycka M; Malinowska A; Horwacik I; Rokita H
Front Pharmacol; 2024; 15():1351536. PubMed ID: 38495105
[TBL] [Abstract][Full Text] [Related]
22. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors.
Murray JL; Cunningham JE; Brewer H; Mujoo K; Zukiwski AA; Podoloff DA; Kasi LP; Bhadkamkar V; Fritsche HA; Benjamin RS
J Clin Oncol; 1994 Jan; 12(1):184-93. PubMed ID: 8270976
[TBL] [Abstract][Full Text] [Related]
23. Enhancement of in vitro and in vivo anti-tumor activity of anti-GD2 monoclonal antibody 220-51 against human neuroblastoma by granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor.
Fukuda M; Horibe K; Furukawa K
Int J Mol Med; 1998 Oct; 2(4):471-5. PubMed ID: 9857237
[TBL] [Abstract][Full Text] [Related]
24. Preclinical evaluation of the Aurora kinase inhibitors AMG 900, AZD1152-HQPA, and MK-5108 on SW-872 and 93T449 human liposarcoma cells.
Noronha S; Alt LAC; Scimeca TE; Zarou O; Obrzut J; Zanotti B; Hayward EA; Pillai A; Mathur S; Rojas J; Salamah R; Chandar N; Fay MJ
In Vitro Cell Dev Biol Anim; 2018 Jan; 54(1):71-84. PubMed ID: 29197031
[TBL] [Abstract][Full Text] [Related]
25. An anti-GD2 monoclonal antibody enhances apoptotic effects of anti-cancer drugs against small cell lung cancer cells via JNK (c-Jun terminal kinase) activation.
Yoshida S; Kawaguchi H; Sato S; Ueda R; Furukawa K
Jpn J Cancer Res; 2002 Jul; 93(7):816-24. PubMed ID: 12149148
[TBL] [Abstract][Full Text] [Related]
26. High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model.
Richman SA; Nunez-Cruz S; Moghimi B; Li LZ; Gershenson ZT; Mourelatos Z; Barrett DM; Grupp SA; Milone MC
Cancer Immunol Res; 2018 Jan; 6(1):36-46. PubMed ID: 29180536
[TBL] [Abstract][Full Text] [Related]
27. Generation of a human anti-idiotypic antibody that mimics the GD2 antigen.
Saleh MN; Stapleton JD; Khazaeli MB; LoBuglio AF
J Immunol; 1993 Sep; 151(6):3390-8. PubMed ID: 8376782
[TBL] [Abstract][Full Text] [Related]
28. Structural Basis of GD2 Ganglioside and Mimetic Peptide Recognition by 14G2a Antibody.
Horwacik I; Golik P; Grudnik P; Kolinski M; Zdzalik M; Rokita H; Dubin G
Mol Cell Proteomics; 2015 Oct; 14(10):2577-90. PubMed ID: 26179345
[TBL] [Abstract][Full Text] [Related]
29. Monoclonal antibodies to disialogangliosides: characterization of antibody-mediated cytotoxicity against human melanoma and neuroblastoma cells in vitro.
Kawashima I; Tada N; Fujimori T; Tai T
J Biochem; 1990 Jul; 108(1):109-15. PubMed ID: 2121721
[TBL] [Abstract][Full Text] [Related]
30. Cancer vaccine with mimotopes of tumor-associated carbohydrate antigens.
Kozbor D
Immunol Res; 2010 Mar; 46(1-3):23-31. PubMed ID: 19763891
[TBL] [Abstract][Full Text] [Related]
31. Cytotoxicity of adriamycin-containing immunoliposomes targeted with anti-ganglioside monoclonal antibodies.
Ohta S; Igarashi S; Honda A; Sato S; Hanai N
Anticancer Res; 1993; 13(2):331-6. PubMed ID: 8517645
[TBL] [Abstract][Full Text] [Related]
32. Analysis of a murine anti-ganglioside GD2 monoclonal antibody expressing both IgG2a and IgG3 isotypes: monoclonality, apoptosis triggering, and activation of cellular cytotoxicity on human melanoma cells.
Lin CC; Shen YC; Chuang CK; Liao SK
Adv Exp Med Biol; 2001; 491():419-29. PubMed ID: 14533812
[TBL] [Abstract][Full Text] [Related]
33. Electrophysiological characteristics of primary afferent fibers after systemic administration of anti-GD2 ganglioside antibody.
Xiao WH; Yu AL; Sorkin LS
Pain; 1997 Jan; 69(1-2):145-51. PubMed ID: 9060025
[TBL] [Abstract][Full Text] [Related]
34. Immunocytochemical study on internalization of anti-carbohydrate monoclonal antibodies.
Kusano A; Ohta S; Shitara K; Hanai N
Anticancer Res; 1993; 13(6A):2207-12. PubMed ID: 8297135
[TBL] [Abstract][Full Text] [Related]
35. A novel O-acetylated ganglioside detected by anti-GD2 monoclonal antibodies.
Ye JN; Cheung NK
Int J Cancer; 1992 Jan; 50(2):197-201. PubMed ID: 1730513
[TBL] [Abstract][Full Text] [Related]
36. Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse.
Raffaghello L; Marimpietri D; Pagnan G; Pastorino F; Cosimo E; Brignole C; Ponzoni M; Montaldo PG
Cancer Lett; 2003 Jul; 197(1-2):205-9. PubMed ID: 12880983
[TBL] [Abstract][Full Text] [Related]
37. Preclinical evaluation in nonhuman primates of murine monoclonal anti-idiotype antibody that mimics the disialoganglioside GD2.
Sen G; Chakraborty M; Foon KA; Reisfeld RA; Bhattacharya-Chatterjee M
Clin Cancer Res; 1997 Nov; 3(11):1969-76. PubMed ID: 9815586
[TBL] [Abstract][Full Text] [Related]
38. Combined sialic acid and histone deacetylase (HDAC) inhibitor treatment up-regulates the neuroblastoma antigen GD2.
van den Bijgaart RJE; Kroesen M; Wassink M; Brok IC; Kers-Rebel ED; Boon L; Heise T; van Scherpenzeel M; Lefeber DJ; Boltje TJ; den Brok MH; Hoogerbrugge PM; Büll C; Adema GJ
J Biol Chem; 2019 Mar; 294(12):4437-4449. PubMed ID: 30670592
[TBL] [Abstract][Full Text] [Related]
39. The dual PI3K/mTOR inhibitor NVP-BEZ235 and chloroquine synergize to trigger apoptosis via mitochondrial-lysosomal cross-talk.
Seitz C; Hugle M; Cristofanon S; Tchoghandjian A; Fulda S
Int J Cancer; 2013 Jun; 132(11):2682-93. PubMed ID: 23151917
[TBL] [Abstract][Full Text] [Related]
40. Cell cycle arrest and apoptosis induced by O-acetyl-GD2-specific monoclonal antibody 8B6 inhibits tumor growth in vitro and in vivo.
Cochonneau D; Terme M; Michaud A; Dorvillius M; Gautier N; Frikeche J; Alvarez-Rueda N; Bougras G; Aubry J; Paris F; Birklé S
Cancer Lett; 2013 Jun; 333(2):194-204. PubMed ID: 23370223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
